Clinical Trials Browser

Bronchiolitis Obliterans Syndrome × Rituximab × Clear all

NCT03112603 2025-08-12

A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)

Phase 3 Completed

330 enrolled 32 charts 1 FDA

Bronchiolitis Obliterans Syndrome, Graft vs Host Disease

NCT01994382 2022-04-05

Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL

Phase 1/2 Completed

260 enrolled 33 charts

DermatologicLymphoidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Leukemia, Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous

NCT00280241 2016-02-04

Protocol for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia

Phase 2 Completed

65 enrolled 8 charts

LymphoidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Leukemia, Leukemia, Lymphocytic, Chronic, B-Cell

NCT00379587 2014-03-19

Rituximab for Prevention of Chronic GVHD

Phase 1/2 Completed

65 enrolled 9 charts

Other hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Hematologic Neoplasms